Smith | Division of Hematology & Oncology

Dr. Stephen Smith

Claim this profile

Fred Hutch/University of Washington Cancer Consortium

Studies Follicular Lymphoma
Studies Lymphoma
9 reported clinical trials
27 drugs studied

Area of expertise

1Follicular Lymphoma
Stephen Smith has run 5 trials for Follicular Lymphoma. Some of their research focus areas include:
CD19 positive
CCND1 positive
t(11;14) positive
2Lymphoma
Stephen Smith has run 5 trials for Lymphoma. Some of their research focus areas include:
CD19 positive
CCND1 positive
t(11;14) positive

Affiliated Hospitals

Image of trial facility.
Fred Hutch/University Of Washington Cancer Consortium
Image of trial facility.
University Of Washington Medical Center - Montlake

Clinical Trials Stephen Smith is currently running

Image of trial facility.

Immunotherapy + Chemotherapy

for Lymphoma

This phase I/II trial tests the safety of tafasitamab, retifanlimab, and rituximab (TRR) as a prephase treatment and in combination with standard therapy consisting off cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or polatuzumab vedotin, cyclophosphamide, doxorubicin, and prednisone (PolaCHP) in patients with untreated diffuse large B-cell lymphoma. Tafasitamab, retifanlimab, and rituximab are monoclonal antibodies. Tafasitamab binds to a protein called CD19, which is found on B-cells (a type of white blood cell) and some types of cancer cells. Rituximab binds to a protein called CD20, which is also found on B-cells and some cancer cells. These monoclonal antibodies may help the immune system kill cancer cells. Immunotherapy with other monoclonal antibodies, such as retifanlimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as CHOP and PolaCHP, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving TRR in combination with CHOP or PolaCHP may kill more cancer cells.
Recruiting1 award Phase 1 & 2
Image of trial facility.

Loncastuximab Tesirine

for B-Cell Lymphoma

This trial is testing a new treatment called loncastuximab tesirine for patients whose B-cell cancers have returned or don't respond to other treatments. The treatment uses a special protein to find cancer cells and deliver a chemotherapy drug directly to them. Patients receive this treatment periodically and are monitored for several years after treatment. Loncastuximab tesirine has been previously tested in an earlier study for similar conditions.
Recruiting2 awards Phase 2

More about Stephen Smith

Clinical Trial Related2 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 4 Active Clinical Trials
Treatments Stephen Smith has experience with
  • Rituximab
  • Cyclophosphamide
  • Doxorubicin
  • Rituximab And Hyaluronidase Human
  • Obinutuzumab
  • Pembrolizumab

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
What does Stephen Smith specialize in?
Is Stephen Smith currently recruiting for clinical trials?
Are there any treatments that Stephen Smith has studied deeply?
What is the best way to schedule an appointment with Stephen Smith?
What is the office address of Stephen Smith?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security